Sarepta says yet to receive new date for panel review of muscle wasting drug
 

Sarepta says yet to receive new date for panel review of muscle wasting drug
(Reuters) - Drug developer Sarepta Therapeutics Inc said it had **t received a rescheduled date for the review of its drug for a rare muscle wasting disorder by an FDA advisory panel and would slash about 17 percent of its workforce.


http://rc.feedsportal.com/r/24739412...32/rc/1/rc.img

http://rc.feedsportal.com/r/24739412...32/rc/2/rc.img

http://rc.feedsportal.com/r/24739412...32/rc/3/rc.img

http://da.feedsportal.com/r/24739412...5/sc/32/a2.img
http://adchoice.feedsportal.com/r/24.../sc/32/ach.imghttp://pi.feedsportal.com/r/24739412.../sc/32/a2t.imghttp://pi2.feedsportal.com/r/2473941...sc/32/a2t2.imghttp://i1.wp.com/reuters.us.feedspor...f?resize=1%2C1http://feeds.feedburner.com/~ff/reut...?d=yIl2AUoC8zA http://feeds.feedburner.com/~ff/reut...yo:F7zBnMyn0Lo http://feeds.feedburner.com/~ff/reut...yo:V_sGLiPBpWU
http://feeds.feedburner.com/~r/reute...~4/Sk1RNuZD7d8